Brazil Kidney Cancer Therapeutics Market Analysis

Brazil Kidney Cancer Therapeutics Market Analysis


$ 3999

The Brazil Kidney Cancer Therapeutics Market was valued at $157.25 Mn in 2023 and is predicted to grow at a CAGR of 5.86% from 2023 to 2030, to $234.27 Mn by 2030. Brazil Kidney Cancer Therapeutics Market is growing due to an Increase in Geriatric Population, a Rise in Lifestyle disorders, and Growing Pipeline of Novel Therapies. Amgen Inc., Bayer AG, F. Hoffmann-La Roche, Bristol Myers Squibb, and Abbott Laboratories are the major companies operating in the Brazil Kidney Cancer Therapeutics Market.

ID: IN10BRPH350 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Najib Shaikh

Buy Now

Brazil Kidney Cancer Therapeutics Market Analysis Executive Summary

Brazil's Kidney Cancer Therapeutics Market is at around $157.25 Mn in 2023 and is projected to reach $234.27 Mn in 2030, exhibiting a CAGR of 5.86% during the forecast period.

Kidney cancer is characterized by the development of malignant tumors in the kidneys. The elderly, usually in their 50s to 70s, are the main victims of renal cell carcinoma. Typical symptoms include blood in the urine, tiredness, pain in the back or flanks, an abdominal bulge or lump, lack of appetite, and accidental weight loss. Although the precise origin of kidney cancer is frequently unknown, risk factors like smoking, obesity, high blood pressure, and family history might raise the disease's chance of occurring.  The most popular form of treatment for chronic renal illness is kidney transplantation.

Kidney cancer is the 13th most common cancer in Brazil with nearly 12,000 new cases reported in 2020. Renal cell carcinomas (RCCs) comprise 2-3% of all adult cancer cases and 80–85% of cases of kidney cancer. Male patients outweigh female patients by a ratio of 3:2. Numerous known risk factors include obesity, hypertension, smoking, and acquired renal cystic disease. 1-3% of cases are inherited, although the majority are random. The market is growing due to an increase in the Geriatric Population, a Rise in Lifestyle disorders, and a Growing Pipeline of Novel Therapies. However Regulatory barriers, Side effects, and High cost of treatment restrict the growth and potential of the market.

Pfizer Inc. (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.) are key players in the Brazil Kidney Cancer Therapeutics Market.

Brazil Kidney Cancer Therapeutics Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Increase in Geriatric Population: In Brazil, the percentage of the old population has increased dramatically since 1950. As an example, the number of elderly people in 1950 was just approximately 2.6 Mn, or 4.9% of the total population. The number of senior people reached 30.1 Mn in 2020 or roughly 14.3% of the total population. In addition, projections indicate that the number of elderly individuals would rise to 73.4 Mn by 2060. Given that the elderly population is more prone to cancer, this is expected to propel the market for cancer therapy.

Rise in Lifestyle Disorders: In Brazil, more individuals are leading sedentary lifestyles as a result of rising disposable income and urbanization. Because of this, the population is becoming more susceptible to lifestyle disorders like obesity and hypertension. As an example, the percentage of people who are obese rose from 12.2% in 2003 to approximately 22.1% in 2021. Furthermore, the percentage of overweight people in the population rose from 43.3% in 2003 to 61.7% in 2019. In addition, it is projected that 40.7% of Brazilians have high blood pressure. Given that obesity and hypertension are two of the main risk factors for cancer, this is what is driving demand.

Growing Pipeline of Novel Therapies: A significant breakthrough in oncology has been made possible by the pharmaceutical industry's investment in the creation of innovative treatments for kidney cancer. Targeted therapies, which attempt to interfere with certain molecular processes involved in the development and spread of cancer, are one area in which this dedication is very clear. With fewer side effects than conventional chemotherapy, targeted therapies have the potential to be more effective because they specifically target certain pathways. Additionally, a novel strategy for treating kidney cancer is immunotherapies, which use the body's immune system to identify and destroy cancer cells.

Market Restraints

Regulatory Barrier: New kidney cancer treatments and diagnostics must receive regulatory approval through a complex process that includes demanding clinical trials and regulatory restrictions. By carefully examining the results of several preclinical and clinical investigations, these regulatory agencies assess the safety, effectiveness, and caliber of investigational items, making sure they fulfill the requirements for patient use. Treatments for kidney cancer usually undergo multiphase clinical trials: Phase I studies to test safety, Phase II trials to assess efficacy in a broader patient group, and Phase III trials to confirm efficacy and track side effects.

Side effects: The side effects of kidney cancer drugs can vary depending on the specific treatment chosen. Kidney cancer is treated with a number of typical side effects of different therapeutic classes, such as immunotherapies and targeted treatments. The side effects of targeted treatments, like sunitinib, pazopanib, and cabozantinib, can include thinning hair, constipation, diarrhea, or exhaustion; vomiting; nausea; increased blood pressure; hand-foot syndrome; and problems with the skin, such as rash, dryness, or discoloration; and changes in blood pressure.

High cost of treatment: One key issue that may hinder market expansion is the high cost of cancer therapy. The yearly mean cost per patient for cancer therapy in Brazil was $9,572.3, with the range being $5,782.1 for breast cancer and $16,656 for cervical cancer, according to data from the US National Institute of Health and Health (NIH). Given that the average per capita income of the nation is only expected to be $14,550 in 2020, this may render high-quality cancer therapy unaffordable to the great majority of the population. Not only that, but Brazil offers free public healthcare; nevertheless, due to overcrowding in the facilities, wait times for medical services can be very lengthy.

Regulatory Landscape and Reimbursement Scenario

The Brazilian Health Regulatory Agency (ANVISA), which oversees healthcare goods and services from clinical trial authorization to post-marketing surveillance, is responsible for granting marketing authorization (MA) in Brazil. The 10-year MA by Anvisa certifies that medications are high-quality, safe, and effective. Companies must also apply for maximum pricing clearance from the Drug Market Regulatory Chamber (CMED) in order to be permitted to enter the Brazilian market.

All citizens and visitors, including those without legal status, have free and full access to a range of services, including hospital, mental health, outpatient specialty, primary, and prescription drug coverage. There is no need for an application procedure. When it comes to medical treatments, there is no cost-sharing. Approximately 25% of Brazilians, primarily those from middle-class and upper-class backgrounds, possess private health insurance in order to avoid obstacles when seeking medical attention. Costs associated with purchasing health-related items and private health insurance are deductible from taxes.

Competitive Landscape

Here are some of the major key players in the Brazil Kidney Cancer Therapeutics Market:

Key Players

  • Abbott (U.S.)
  • Abbott Laboratories
  • Amgen Inc.6.1.3 Bayer AG
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck
  • Novartis International AG
  • Pfizer Inc
  • Sanofi
  • AstraZeneca

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Brazil Kidney Cancer Therapeutics Market Segmentation

By Product 

  • Bevacizumab 
  • Everolimus
  • Cabozantinib
  • Axitinib
  • Sorafenib
  • Temsirolimus
  • Sunitinib
  • Pazopanib 

By End-users   

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Centers

By Distribution Channel

  • Hospital Pharmacies 
  • Retail Pharmacies
  • Online Pharmacies 

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 16 July 2024
Updated by: Dr. Purav Gandhi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up